Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-05T19:36:40.575Z Has data issue: false hasContentIssue false
  • English
  • Français

Preoperative oral celecoxib versus preoperative oral rofecoxib for pain relief after thyroid surgery

Published online by Cambridge University Press:  11 July 2005

B. Karamanlıoğlu ,
C. Arar ,
A. Alagöl ,
A. Çolak ,
I. Gemlik  and
N. Süt
B. Karamanlıoğlu
Affiliation:
Trakya University Faculty of Medicine, Department of Anaesthesiology and Reanimation, Edirne, Turkey
C. Arar
Affiliation:
Trakya University Faculty of Medicine, Department of Anaesthesiology and Reanimation, Edirne, Turkey
A. Alagöl
Affiliation:
Trakya University Faculty of Medicine, Department of Anaesthesiology and Reanimation, Edirne, Turkey
A. Çolak
Affiliation:
Trakya University Faculty of Medicine, Department of Anaesthesiology and Reanimation, Edirne, Turkey
I. Gemlik
Affiliation:
Trakya University Faculty of Medicine, Department of Anaesthesiology and Reanimation, Edirne, Turkey
N. Süt
Affiliation:
Trakya University Faculty of Medicine, Department of Biostatistics, Edirne, Turkey
Get access

Extract

Summary

Background and objective: The study compared the analgesic efficacy and safety of two preoperatively administered cyclo-oxygenase-2 inhibitors, celecoxib and rofecoxib.

Methods: Ninety adult patients undergoing thyroid surgery were divided into three groups (each n = 30). They were given a single oral dose of placebo, celecoxib 200 mg or rofecoxib 50 mg 1 h before induction of anaesthesia. All patients received a standard anaesthetic. Intraoperative blood loss was measured. Pain scores, sedation scores, heart rate, mean arterial pressure and respiratory rate were noted at 0, 1, 2, 4, 6, 12 and 24 h postoperatively. Analgesic (meperidine) requirements and adverse effects were recorded during the first postoperative 24 h.

Results: Compared with placebo, pain scores were significantly lower with rofecoxib at all time points (P < 0.05) and were significantly lower with celecoxib (P < 0.05) during the first 4 h. Pain scores were significantly lower with rofecoxib compared with celecoxib at 6, 12 and 24 h (P < 0.05). The average cumulative 24 h meperidine dose was significantly lower with both celecoxib (54.9 ± 34.4 mg) and rofecoxib (42.8 ± 40.9 mg) compared with placebo (76.8 ± 6.2 mg) (P < 0.01 and P < 0.001, respectively). There were no differences in the intraoperative blood loss, heart rate, mean arterial pressure, respiratory rate, sedation scores and incidence of adverse effects among groups.

Conclusions: The preoperative administration of rofecoxib 50 mg and less so of celecoxib 200 mg provide a significant analgesic benefit with regard to postoperative pain relief and decrease in additional opioid requirements after thyroid surgery.

Keywords

ANALGESIC TECHNIQUES, preoperativeANALGESICS, NON-OPIOID, celecoxib, paracetamol, rofecoxibANALGESICS, OPIOID, meperidinePAIN, postoperativeSURGERY, thyroid
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 20 , Issue 6 , June 2003 , pp. 490 - 495
Copyright
© 2003 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Rockemann MG, Seeling W, Bischof C, Borstinghaus D, Steffen P, Georgieff M. Prophylactic use of epidural mepivacaine/morphine, systemic diclofenac, and metamizole reduces postoperative morphine consumption after major abdominal surgery. Anesthesiology 1996; 84: 1027–1034.Google Scholar
Richmond CE, Bromley LM, Woolf CJ. Preoperative morphine pre-empts postoperative pain. Lancet 1993; 342: 73–75.Google Scholar
Power I, Barratt S. Analgesic agents for the postoperative period. Nonopioids. Surg Clin North Am 1999; 79: 275–295.Google Scholar
Katz J, Kavanagh BP, Sandler AN, et al. Preemptive analgesia. Clinical evidence of neuroplasticity contributing to postoperative pain. Anesthesiology 1992; 77: 439–446.Google Scholar
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nat New Biol 1971; 231: 232–235.Google Scholar
Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307–314.Google Scholar
Kam PCA, Power I. New selective COX-2 inhibitors. Pain Reviews 2000; 7: 3–13.Google Scholar
Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999; 65: 336–347.Google Scholar
Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000; 59: 957–980.Google Scholar
Hubbard RC, Mehlisch DR, Jasper DR, Nugent MJ, Yu S, Isakson PC. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in acute pain model (abstract). J Invest Med 1996; 44: 293A.Google Scholar
Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, Seidenberg B. Analgesic efficacy of the cyclooxygenase-2- specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther 1999; 21: 943–953.Google Scholar
Malmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardins PJ. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. Clin Ther 1999; 21: 1653–1663.Google Scholar
Reuben SS, Connelly NR. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg 2000; 91: 1221–1225.Google Scholar
Reuben SS, Connelly NR, Lurie S, Klatt M, Gibson CS. Dose–response of ketorolac as an adjunct to patient-controlled analgesia morphine in patients after spinal fusion surgery. Anesth Analg 1998; 87: 98–102.Google Scholar
Dahl JB, Kehlet H. Non-steroidal anti-inflammatory drugs: rationale for use in severe postoperative pain. Br J Anaesth 1991; 66: 703–712.Google Scholar
Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013–12017.Google Scholar
Mehlisch DR, Hubbard RC, Isakson P. Analgesic efficacy and plasma levels of a highly selective inhibitor of COX-2 (SC-58635; SC) in patients with post-surgical dental pain. Clin Pharmacol Ther 1997; 61: 195.Google Scholar
Mehlisch DR, Mills S, Sandler M, et al. Ex vivo assay of COX-2 inhibition predicts analgesic efficacy in post-surgical dental pain with MK-966. Clin Pharmacol Ther 1998 [Abstracts of the 99th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics 1998]; 63: 139.Google Scholar
Chang DJ, Christensen KS, Bulloch SE, et al. Superior efficacy of rofecoxib compared to codeine with acetaminophen for the treatment of acute pain. Acad Emerg Med 2001; 8: 429.Google Scholar
Morrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg B. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea. A randomized clinical trial. Obstet Gynecol 1999; 94: 504–508.Google Scholar
Reicin A, Brown J, Jove M, et al. Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain. Am J Orthop 2001; 30: 40–48.Google Scholar
Huang JJ, Taguchi A, Hsu H, Andriole GL Jr, Kurz A. Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: a prospective, randomized, double-blinded, placebo-controlled trial. J Clin Anesth 2001; 13: 94–97.Google Scholar
Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40: 1109–1120.Google Scholar
Bensen WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000; 27: 1876–1883.Google Scholar